Circulating tumor cells

References

• Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013; 8:83 - 96; http://dx.doi.org/10.1007/s11523-013-0281-x; PMID: 23645285
   PubMed Web of Science ®Google Scholar
• Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis 2012; 14:3 - 17; http://dx.doi.org/10.1111/j.1463-1318.2010.02439.x; PMID: 21040359
   PubMed Web of Science ®Google Scholar
• Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010; 2010:150960; http://dx.doi.org/10.1155/2010/150960; PMID: 20617134
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486:532 - 6; PMID: 22722830
   PubMed Web of Science ®Google Scholar
• Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 2012; 14:207 - 14; PMID: 23021375
   PubMed Web of Science ®Google Scholar
• Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 2013; 133:1914 - 25; http://dx.doi.org/10.1002/ijc.28153; PMID: 23494461
   PubMed Web of Science ®Google Scholar
• Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72:4875 - 82; http://dx.doi.org/10.1158/0008-5472.CAN-12-2217; PMID: 23002210
   PubMed Web of Science ®Google Scholar
• Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108:479 - 85; http://dx.doi.org/10.1038/bjc.2012.581; PMID: 23299535
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59:110 - 8; http://dx.doi.org/10.1373/clinchem.2012.194258; PMID: 23014601
   PubMed Web of Science ®Google Scholar
• Miller MC, Doyle GV, Terstappen LW. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol 2010; 2010:617421; http://dx.doi.org/10.1155/2010/617421; PMID: 20016752
   PubMedGoogle Scholar
• Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJ, Vos AH, Nagtegaal ID, Terstappen LW, Punt CJ. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010; 21:1006 - 12; http://dx.doi.org/10.1093/annonc/mdp463; PMID: 19861577
   PubMed Web of Science ®Google Scholar
• Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist 2012; 17:947 - 55; http://dx.doi.org/10.1634/theoncologist.2012-0048; PMID: 22643538
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20:1223 - 9; http://dx.doi.org/10.1093/annonc/mdn786; PMID: 19282466
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:3213 - 21; http://dx.doi.org/10.1200/JCO.2007.15.8923; PMID: 18591556
   PubMed Web of Science ®Google Scholar
• Bidard FC, Ferrand FR, Huguet F, Hammel P, Louvet C, Malka D, Boige V, Ducreux M, Andre T, de Gramont A, et al. Disseminated and circulating tumor cells in gastrointestinal oncology. Crit Rev Oncol Hematol 2012; 82:103 - 15; http://dx.doi.org/10.1016/j.critrevonc.2011.05.008; PMID: 21680197
   PubMed Web of Science ®Google Scholar
• Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6:519 - 27; http://dx.doi.org/10.1038/nrclinonc.2009.111; PMID: 19636327
   PubMed Web of Science ®Google Scholar
• De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12:594 - 603; http://dx.doi.org/10.1016/S1470-2045(10)70209-6; PMID: 21163703
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4:e7287; http://dx.doi.org/10.1371/journal.pone.0007287; PMID: 19806185
   PubMed Web of Science ®Google Scholar
• Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Börger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman M, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012; 12:292; http://dx.doi.org/10.1186/1471-2407-12-292; PMID: 22804917
   PubMed Web of Science ®Google Scholar
• Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013; 133:1259 - 65; http://dx.doi.org/10.1002/ijc.28106; PMID: 23404247
   PubMed Web of Science ®Google Scholar
• Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013; 8:277 - 302; http://dx.doi.org/10.1146/annurev-pathol-020712-163923; PMID: 23092187
   PubMed Web of Science ®Google Scholar
• Marusyk A, Polyak K. Cancer. Cancer cell phenotypes, in fifty shades of grey. Science 2013; 339:528 - 9; http://dx.doi.org/10.1126/science.1234415; PMID: 23372002
   PubMed Web of Science ®Google Scholar
• Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetecTable 3irculating tumor cells. Int J Cancer 2011; 129:417 - 23; http://dx.doi.org/10.1002/ijc.25690; PMID: 20857493
   PubMed Web of Science ®Google Scholar
• Gazzaniga P, Raimondi C, Gradilone A, Di Seri M, Longo F, Cortesi E, Frati L. Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. Ann Oncol 2011; 22:1929 - 30; http://dx.doi.org/10.1093/annonc/mdr292; PMID: 21633048
   PubMed Web of Science ®Google Scholar
• Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85:314 - 23; http://dx.doi.org/10.2183/pjab.85.314; PMID: 19838011
   PubMed Web of Science ®Google Scholar
• Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, et al. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet 2012; 8:e1002723; http://dx.doi.org/10.1371/journal.pgen.1002723; PMID: 22654675
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer Version 2. 2013
   Google Scholar
• Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16:790 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-2446; PMID: 20103678
   PubMed Web of Science ®Google Scholar
• Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104:1020 - 6; http://dx.doi.org/10.1038/bjc.2011.26; PMID: 21364579
   PubMed Web of Science ®Google Scholar
• Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009; 15:4508 - 13; http://dx.doi.org/10.1158/1078-0432.CCR-08-3179; PMID: 19549774
   PubMed Web of Science ®Google Scholar
• Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, Mauermann O, Izbicki JR, Pantel K, Riethdorf S. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013; 59:252 - 60; http://dx.doi.org/10.1373/clinchem.2012.188557; PMID: 23136247
   PubMed Web of Science ®Google Scholar
• Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, Kraan J, Lalmahomed Z, van Galen A, de Weerd V, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013; 133:130 - 41; http://dx.doi.org/10.1002/ijc.27987; PMID: 23233388
   PubMed Web of Science ®Google Scholar
• Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, Chiadini E, Passardi A, Frassineti GL, Ragazzini A, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett 2013; 335:225 - 31; http://dx.doi.org/10.1016/j.canlet.2013.02.015; PMID: 23419522
   PubMed Web of Science ®Google Scholar
• Parsons BL, Myers MB. Personalized cancer treatment and the myth of KRAS wild-type colon tumors. Discov Med 2013; 15:259 - 67; PMID: 23636143
   PubMed Web of Science ®Google Scholar
• Zeng M, Kikuchi H, Pino MS, Chung DC. Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One 2010; 5:e10966; http://dx.doi.org/10.1371/journal.pone.0010966; PMID: 20532039
   PubMedGoogle Scholar
• De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812 - 20; http://dx.doi.org/10.1001/jama.2010.1535; PMID: 20978259
   PubMed Web of Science ®Google Scholar
• Lankiewicz S, Zimmermann S, Hollmann C, Hillemann T, Greten TF. Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol 2008; 2:349 - 55; http://dx.doi.org/10.1016/j.molonc.2008.09.001; PMID: 19383356
   PubMed Web of Science ®Google Scholar